Drug Trial Radar · NCT03056326
A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Nov 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Nov 2016
Primary completion
Jul 2017
Study completion Jul 2017
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Feb 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Human Neutrophil Elastase (HNE) plays a pivotal role in innate immunity and in neutrophilic lung inflammation that characterized many diseases. CHF 6333 is a potent and 24h-durable inhibitor of HNE, developed as Dry Powder Inhaler (DPI) formulation. This study is designed to investigate the tolerability, safety and pharmacokinetics of inhaled CHF6333 DPI in healthy male subjects. The study will comprise two parts: Part 1 will consist of two alternated cohorts of healthy male subjects to assess the safety, tolerability and pharmacokinetics of Single Ascending Dose (SAD) of CHF6333. Part 2 will consist of four sequential cohorts of healthy male subjects to assess the safety, tolerability and pharmacokinetics of Multiple Ascending Dose (MAD) of CHF6333
Conditions
- Non-Cystic Fibrosis Bronchiectasis
- Cystic Fibrosis
Interventions
CHF6333 (Part 1 - SAD)Drug
Single doses of CHF6333 at each period
Placebo (Part 1 - SAD)Drug
Single doses of placebo matching CHF6333 at each period
CHF6333 (Part 2 - MAD)Drug
once daily multiple doses of CHF6333 for 14 days
Placebo (Part 2 - MAD)Drug
once daily multiple doses of placebo matching CHF6333 for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Part 1 from Day 1 to 5, Part 2 from Day 1 to 15
- Change in Vital signsTime frame: Part 1 from Day 1 to 5, Part 2 from Day 1 to 15
- Heart RateTime frame: Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15
- QTcF intervalTime frame: Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15
- PR intervalTime frame: Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15
- QRS intervalTime frame: Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15
- Holter recording abnormalitiesTime frame: Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15
- FEV1Time frame: Part 1 Day 1-2, Part 2 Day 1-14-15
- Clinical chemistry and haematologyTime frame: Part 1 Day 1-5, Part 2 Day 1-15
- UrinalysisTime frame: Part 1 Day 1-5, Part 2 Day 1-15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SGS Life Sciences
Antwerp, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.